Brainstorm Cell Therapeutics earnings release, May 15, 2026

Brainstorm Cell Therapeutics Inc. (BCLI) · Form 8-K, Item 2.02 · Filed · SEC filing

BrainStorm Cell Therapeutics Announces First

Quarter 2026 Financial Results and Provides Corporate Update

NEW YORK, May 15,

2026 /PRNewswire/

-- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the three months ended March 31, 2026, and provided a corporate update.

“The team at BrainStorm is focused on completing the final steps required to initiate our planned Phase 3 ENDURANCE study of NurOwn in ALS,” said Chaim Lebovits, President and CEO.

“Site activation, manufacturing readiness, and regulatory engagement are all progressing, and, subject to securing the necessary financing, we are well positioned to move into the enrollment phase. ENDURANCE is designed to enroll patients with earlier-stage disease, where NurOwn's mechanism has the greatest opportunity to demonstrate benefit. ALS is a devastating illness with limited therapeutic options, and we remain committed to the community to complete NurOwn's development and make it available to those who need it."

Recent Highlights

NurOwn® (MSC-NTF) for ALS

Corporate

Financial Results for the Three Months Ended March 31, 2026

BRAINSTORM CELL THERAPEUTICS INC. AND

Financial statements

Income Statement

Three months ended — (Except share and per share amounts) (in thousands)

Three months ended – March 31, – 2026 – UnauditedThree months ended – March 31, – 2025 – Unaudited
Operating expenses:Research and development, net7621,304
Operating expenses:General and administrative1,2841,785
Operating expenses:Operating loss-2,046-3,089
Operating expenses:Financial income (expense), net-8146
Operating expenses:Change in fair value of warrant liability179
Operating expenses:Net loss-2,127-2,864
Operating expenses:Basic and diluted net loss per share-0.19-0.45
Operating expenses:Weighted average number of shares outstanding used in computing basic and diluted net loss per share11,034,7756,342,002

Balance Sheet

December 31, — (Except share and per share amounts) (in thousands)

March 31, – 2026 – Unaudited – U.S. $ in thousandsDecember 31, – 2025 – Audited – U.S. $ in thousands
Current Assets:Cash and cash equivalents1529
Current Assets:Other accounts receivable12286
Current Assets:Prepaid expenses and other current assets47192
Current Assets:Total current assets184307
Long-Term Assets:Prepaid expenses and other long-term assets2525
Long-Term Assets:Restricted Cash191247
Long-Term Assets:Right of use asset (Note 3)157208
Long-Term Assets:Property and equipment, net198235
Long-Term Assets:Total Long-Term Assets571715
Long-Term Assets:Total assets7551,022
Current Liabilities:Accounts payable7,3177,067
Current Liabilities:Accrued expenses414396
Current Liabilities:Short-term loans (Note 6)1,329967
Current Liabilities:Operating lease liability (Note 3)159208
Current Liabilities:Employees related liability2,5452,369
Current Liabilities:Total current liabilities11,76411,007
Current Liabilities:Total liabilities11,76411,007
Stockholders’ Deficit:Stock capital: (Note 4)1616
Common stock $0.00005 par value; 250,000,000 shares authorized and 11,034,775 shares issued and outstandingAdditional paid-in-capital228,161227,058
Common stock $0.00005 par value; 250,000,000 shares authorized and 11,034,775 shares issued and outstandingTreasury stock-116-116
Common stock $0.00005 par value; 250,000,000 shares authorized and 11,034,775 shares issued and outstandingAccumulated deficit-239,070-236,943
Common stock $0.00005 par value; 250,000,000 shares authorized and 11,034,775 shares issued and outstandingTotal stockholders’ deficit-11,009-9,985
Common stock $0.00005 par value; 250,000,000 shares authorized and 11,034,775 shares issued and outstandingTotal liabilities and stockholders’ deficit7551,022

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Brainstorm Cell Therapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.